Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The data suggest that the administration of aprotinin to patients treated with DHCA does not increase the risk of renal dysfunction, however, aProtinin may not ameliorate the problem of perioperative blood loss in DHCA.
Abstract
These data suggest that the administration of aprotinin to patients treated with DHCA does not increase the risk of renal dysfunction. However, aprotinin may not ameliorate the problem of perioperative blood loss in DHCA. Patients with greater requirements for packed red blood cell transfusions or reduced urine production are more likely to have postoperative renal dysfunction. Dopamine may provide renal protection in the setting of DHCA.
